Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC – Get Free Report ) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totaling 2,290,000 shares, a decrease of 8.0% from the August 15th total of 2,490,000 shares. Based on an average daily volume of 370,300 shares, the days-to-cover ratio is currently 6.2 days.

Celcuity Institutional Trading

Institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC purchased a new position in Celcuity in the fourth quarter worth about $21,583,000. Commodore Capital LP raised its stake in Celcuity by 3.6% during the 4th quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock worth $25,566,000 after buying an additional 60,563 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Celcuity in the first quarter valued at $3,545,000. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Celcuity in the second quarter valued at $888,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Celcuity by 1.0% in the first quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock worth $17,898,000 after purchasing an additional 7,821 shares during the last quarter. Institutional investors own 63.33% of the company’s shares.

Celcuity Stock Up 0.2%

Shares of CELC traded up $0.03 on Wednesday, reaching $15.01. The company’s stock had a trading volume of 213,726 shares, compared to its average volume of 282,679. The stock has a market cap of $526.87 million, a PE ratio of -5.39 and a beta of 0.76. The company has a current ratio of 14.95, a quick ratio of 14.95, and a debt-to-equity ratio of 0.54. Celcuity has a twelve month low of $8.39 and a twelve month high of $22.19. The firm has a fifty day moving average of $16.79 and a 200 day moving average of $16.95.

Celcuity (NASDAQ:CELC – Get Your Free Report ) last announced its earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same period in the previous year, the firm posted EPS of ($0.66). equities analysts forecast that Celcuity will post -2.54 EPS for the current year.

Analysts on Wall Street are forecasting an increase

A number of equities analysts have issued reports on CELC shares. Leerink Partners began coverage on Celcuity in a report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price target on the stock. Stifel Nicolaus decreased their target price on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating for the company in a report on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Celcuity in a report on Thursday, August 15th. Lifesci Capital started coverage on Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Celcuity in a research report on Thursday, August 15th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $28.67, based on data from MarketBeat.

See our latest report on CELC

Celcuity Company Profile

(Get a free report)

Celcuity Inc, a clinical-stage biotechnology company, is focused on developing targeted therapies for the treatment of various solid tumors in the United States. The company’s CELsignia diagnostic platform uses the patient’s living tumor cells to identify the specific abnormal cellular process driving the patient’s cancer and the related targeted therapy.

Further reading

Get news and reviews for Celcuity Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celcuity and related companies with MarketBeat.com’s FREE daily email newsletter.